ILTOO Pharma announces that ILT-101 has achieved Orphan Drug Designation

ILTOO Pharma announces that ILT-101 has achieved Orphan Drug Designation. ILTOO Pharma SAS today announced that the European Medicines Agency ( EMA ) and the U.S. Food and Drug Administration ( FDA ) have granted Orphan Drug Designation (ODD) status for ILT-101 , the company’s lead drug for the treatment of amyotrophic lateral sclerosis (ALS).

The release as fetched from its publisher. iltoopharma.com ↗